Will Gilead's Beat-And-Raise Help It Leapfrog Its 50-Day Line Ceiling?

Blockhead
Aug 08

Gilead Sciences (GILD) boosted its full-year outlook after beating Wall Street's top- and bottom-line expectations. Gilead stock is currently hitting a ceiling at its 50-day line.

During the June quarter, the biotech giant earned an adjusted $2.01 per share on $7.08 billion in sales. Earnings were flat year over year, but topped analysts' call for $1.96, according to FactSet. Sales edged 2% higher and narrowly beat expectations for $6.98 billion.

The results prodded Gilead to toe its 2025 outlook higher. The company now expects to earn $7.95 to $8.25 per share. At the midpoint, that's up 20 cents per share from Gilead's previous guidance.

Gilead also calls for $28.3 billion to $28.7 billion in product sales, which excludes revenue from licensing and collaboration agreements. The new guidance is up $100 million from the outlook Gilead issued three months ago.

Gilead stock is consolidating with a buy point at 119.96, according to MarketSurge. But shares were flat in after-hours trading.

Gilead Stock: Biktarvy Easily Beats

Notably, Gilead's biggest moneymaker, HIV drug Biktarvy, brought in $3.53 billion in sales, up 9% and above forecasts for $3.38 billion. Sales of another HIV drug, Descovy, smashed forecasts at $653 million. Analysts called for just $612 million. Descovy sales shot nearly 35% higher.

Descovy is one of the pre-exposure prophylaxis drugs, or PrEP. It can treat HIV. But it can also help prevent HIV from taking hold in at-risk people.

Gilead also won approval in the quarter for a twice-yearly shot to prevent HIV called Yeztugo. Yeztugo is included in Gilead's "other HIV" segment, which brought in $107 million in sales.

Promisingly, sales of cancer drug Tecartus beat expectations at $92 million. Trodelvy brought in $364 million in sales, growing almost 14% and beating calls for $340 million. But Yescarta came up short at $393 million. Analysts called for a slightly stronger $398 million.

Veklury, Gilead's Covid treatment also came in short at $121 million. Analysts projected $200 million. But it's important to note that it's hard to project sales of Covid-tied items, especially during the summer months.

Follow Allison Gatlin on X/Twitter at @AGatlin_IBD.

YOU MAY ALSO LIKE:

Eli Lilly Dives 14% On A Shocking Obesity Setback, Sending Its Rivals Flying

Is Exact Sciences, Down 11%, 'Throwing Good Money At Bad' In Its New Licensing Deal?

Get Timely Buy & Sell Alerts With IBD Leaderboard

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks

Looking For The Next Apple Or Amazon? Start With These S&P 500-Beating Lists

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10